During 1 October 2015 to 29 December 2016, 5 614 cases from 19 Caribbean Public Health Agency (CARPHA) member states (CMS) were tested for arboviral pathogens. Of these, 1 447 cases tested positive for Zika virus. The majority of cases were female (83.0%), of which 614 (51.0%) were pregnant. A total of 59% of cases were 20--39 years old (median, 30 years; range, 5 days--90 years). Rash, fever, and arthralgia affected 87.0%, 63.0%, and 60.0% of all reported cases respectively. Four confirmed cases of congenital syndrome and 121 cases of Guillain--Barré syndrome (GBS), a severe neurological condition in adults, were reported from three and 10 countries respectively.

The emergence of Zika virus in the Caribbean underscores the ongoing challenge posed by arboviral infections and the need for continued vigilance and investment in surveillance systems and innovative prevention and control strategies.

During 2016, the Director General of the World Health Organization (WHO) declared a Public Health Emergency of International Concern (PHEIC) as a result of the complications associated with the Zika virus outbreak in Latin America and the Caribbean ([@B1]). The Caribbean has a long history with arboviral diseases, including yellow fever ([@B2]), dengue ([@B3]), chikungunya ([@B4]), and, more recently, Zika ([@B5], [@B6]). Zika virus (family *Flaviridae*) is transmitted primarily through the bite of infected Aedes mosquitoes, including *Aedes aegypti* ([@B7]). *Ae. aegypti* is broadly distributed throughout the Caribbean ([@B8]), and climate, particularly temperature and rainfall, are key drivers of the vector\'s ecology.

In urban environments, Zika shares a similar epidemiology, clinical presentation, and transmission cycle with chikungunya and dengue but has generally been associated with milder illness ([@B9]). Typical clinical symptoms of the disease include fever, rash, arthralgia, and conjunctivitis ([@B10]). In recent years, Zika virus infection during pregnancy has been shown to be associated with congenital anomalies including microcephaly in babies born to infected mothers ([@B11]). Infection with the virus has also been associated with GBS ([@B12]).

First isolated from a rhesus monkey in the Zika Forest in Uganda in 1947 ([@B7]), serological evidence for the virus in humans during epidemics on Yap Island, Micronesia, in 2007 and French Polynesia in 2013 are well-documented ([@B9], [@B13]). The first autochthonous case of Zika in the Caribbean was reported by Suriname in November 2015 following detection of the virus at the CARPHA laboratory in Trinidad. By December 2016, 105 5851 autochthonous suspected cases and 3 212 confirmed cases were reported by the English- and Dutch-speaking Caribbean CMS ([@B14]).

CARPHA is the regional institution charged with providing public health services to the CMS ([@B15]). One key function of the agency is to support CMS in preparing for and responding to public health emergencies and threats ([@B15]). This is usually performed in close collaboration with regional and international partners. This report describes the epidemiology of laboratory-confirmed Zika cases reported to CARPHA, including links with both congenital syndrome and GBS, for 19 English- and Dutch-speaking Caribbean countries during the epidemic period (1 October 2015--29 December 2016).

MATERIALS AND METHODS
=====================

Setting
-------

The Caribbean comprises countries to the southeast of the Gulf of Mexico and north of the American mainland, east of Central America, and north of South America ([@B16]). Many of the countries have a tropical to subtropical climate with occasional tropical storms and hurricanes. While all CMS are classified as Small Island Developing States, there is a wide range in size---from Guyana, at 219 470 km^2^, to St. Kitts and Nevis, at 360 km^2^---and population---from Montserrat, with just over 5 000 people, to Haiti, with more than 10 000 000 ([@B17]).

CARPHA, established in July 2011, provides CMS with technical support in public health, including regional surveillance, laboratory services, training, and applied research ([@B18]). Health services in CMS are delivered by varying combinations of national public--private mix. In some CMS, primary and secondary care services are provided by health centers or polyclinics, and some hospitals. A small number of CMS can provide tertiary services in-country, while in others, preestablished mechanisms exist with neighboring countries for tertiary service provision. Seven CMS have a National Public Health Laboratory for the provision of specialist laboratory support, while in the remaining 19 this function is provided by a designated hospital laboratory. Diagnostic capacity within CMS differs, and the CARPHA laboratory in Trinidad acts as the regional reference and referral laboratory ([@B19]). CMS routinely refer specimens for testing to CARPHA to support surveillance.

Case definition
---------------

Surveillance for Zika in CMS began on 3 November 2015 following detection of the first autochthonous case of vector-borne transmission of the virus. Syndromic surveillance is well established in the Caribbean, with CMS routinely reporting cases of undifferentiated fever (UDF) to the CARPHA surveillance unit.

Case definitions as outlined in the Pan American Health Organization (PAHO) Zika virus infection Epidemiological Update were modified for the characterization of cases at the beginning of the epidemic ([@B20]). The modified criteria included fever ≥ 37.2 °C and history of travel to a country endemic for Zika or experiencing a Zika virus outbreak ([@B21]). As the epidemic continued and more information regarding clinical presentation of the virus became available, case definitions were reviewed and updated. From April 2016 onward, cases were characterized according to the updated PAHO case definitions ([@B22]). A suspected case was defined as a patient with a rash (usually pruritic and maculopapular) with two or more of the following signs or symptoms: fever (≥ 38.5°C), conjunctivitis (non-purulent or hyperemic), arthralgia, myalgia, and peri-articular edema, who, in the two weeks prior to onset, traveled to or resided in a geographic area with known local transmission of the Zika virus (or known vector presence) or had unprotected sex in the two weeks prior to onset with a person who traveled in the previous eight weeks to a geographic area with known local transmission of the Zika virus (or known vector presence) ([@B22]). Confirmed cases were defined as patients who met the criteria for a suspected case with laboratory confirmation of recent Zika virus infection---i.e., 1) ribonucleic acid (RNA) or Zika virus antigen in any specimen (serum, urine, saliva, tissue, or whole blood), or positive Zika immunoglobulin M (IgM) antibodies and a plaque-reduction neutralization test −90% (PRNT-90) (the serum titer required to reduce viral plaques by 90%) for Zika virus titers equal to 20 and four or more times greater than the titers for other flaviviruses, and exclusion of other flaviviruses, or 2) in autopsy specimens, detection of the viral genome (in fresh or paraffin tissue) by molecular techniques, or detection by immuno-histochemistry ([@B22]).

Due to the documented causal link between Zika and congenital syndrome, the PAHO case definition was used for the identification of congenital cases associated with the virus ([@B20]). A suspected case was a live newborn who presented with microcephaly or other congenital malformation of the central nervous system whose mother had 1) traveled to or resided in an area where Zika virus vectors were present during her pregnancy, or 2) had unprotected sex during pregnancy with a partner who resided in or traveled to an area with the presence of Zika virus vectors ([@B22]). A confirmed case of congenital syndrome associated with Zika virus was defined as a live newborn who met the criteria for a suspected case of congenital syndrome associated with Zika virus, and had a specimen with laboratory detection of Zika virus, with or without detection of other pathogens ([@B22]). The data on Zika virus and congenital syndrome were extracted from country and regional reports and are presented below, along with data on GBS, a disease outcome that has also been linked with the virus.

Sample collection and laboratory analysis
-----------------------------------------

Serum samples from CMS were shipped to the CARPHA--Trinidad laboratory for testing. CMS routinely sent specimens for testing during the outbreak, with the exception of Jamaica and Suriname. These two CMS sent samples to confirm their first cases, as well as a few others; after that, in-country testing was developed with support from CARPHA and PAHO. Samples from Sint Maarten were sent to the Analytisch Diagnostisch Centrum N.V. in Curaçao for testing.

Serum samples from patients in the acute phase of illness were tested using a fluorescent, probe-based, Trioplex real-time reverse transcription--polymerase chain reaction (RT-PCR) assay (TaqMan®, Applied Biosystems, Waltham, MA, USA) developed by the U.S. Centers for Disease Control and Prevention (CDC) for use in detecting chikungunya, dengue, and Zika, in accordance with the PAHO algorithm for detection of Zika virus ([@B23]). An RT-PCR assay was used for detection of Zika virus in samples collected within 1--5 days of onset of illness. Samples taken ≥ 6 days after onset of illness were tested for Zika virus by either RT-PCR or PRNT-90, and by IgM ELISA (Focus Diagnostics Inc., Cypress, CA, USA) for dengue and chikungunya virus. Immunoglobulin G (IgG) testing was not performed. Date of specimen collection was used as a proxy in instances where the date of onset of illness was not provided. Laboratory confirmation for all cases was performed until autochthonous transmission was established within individual CMS. Subsequently, laboratory confirmation was performed on samples from high-risk patients (people \< 5 years old and ≥ 65 years old, hospitalized patients, pregnant women, patients with comorbidities, fatal cases, and suspected cases from new geographic areas).

Data capture and analysis
-------------------------

In December 2015, a Zika database was developed using Microsoft Excel (Microsoft, Redmond, WA, USA) to capture information on specimens submitted to the CARPHA--Trinidad laboratory for Zika testing. Data were uploaded weekly from the CARPHA--Trinidad Laboratory Information System to the Zika database. The General Health Care Section of the Department of Collective Prevention Services at the Ministry of Public Health, Social Development and Labour (*Ministerie van Volksgezondheid, Sociale Ontwikkeling en Arbeid Zaken*, VSA) in Philipsburg, Sint Maarten, submitted a line listing of Zika cases to the CARPHA surveillance unit for inclusion in the Zika database. Data validation was done in collaboration with CMS as necessary. Statistical analyses were performed using Microsoft Excel and Stata version 12 software (StataCorp, College Station, TX, USA). Fisher\'s exact test was used to compare differences in proportions of reported clinical symptoms by age groups and sex; *P* values \< 0.05 were considered statistically significant. Identifying variables were excluded from the dataset that was used for analysis.

RESULTS
=======

Trends over time
----------------

During the epidemic period, 1 October 2015 to 29 December 2016, a total of 5 614 cases from 19 CMS were tested for arboviral pathogens. Of these, 1 447 cases tested positive for Zika virus. While Zika virus was the arboviral pathogen targeted for detection, chikungunya and dengue were also confirmed, at much lower levels ([Figure 1](#f1){ref-type="fig"}). Cases of chikungunya and dengue represented \< 1% of all cases tested. There were no patients with evidence of coinfection with dengue or chikungunya.

![Laboratory-confirmed cases of Zika, chikungunya, and dengue in 19 Caribbean Public Health Agency (CARPHA) member states, 1 October 2015--29 December 2016](rpsp-42-e120-g001){#f1}

The first four laboratory-confirmed cases of Zika were reported by Suriname, with reported onset of illness in October 2015. No significant increase in the UDF syndrome was reported by Suriname during September 2015; however, an increase in reported cases was observed from epidemiological week (EW) 44 (beginning 1 November 2015).

The virus spread rapidly to other CMS, and subsequent cases from the English- and Dutch-speaking Caribbean were confirmed, with reported onset of illness in January 2016. There was a sustained increase in reported cases, which peaked in August 2016. A sharp reduction in cases occurred in September--December 2016.

Laboratory results
------------------

During the review period, there was an overall Zika test positivity of 25.8%. A total of 1 301 of the 1 447 specimens that tested positive for Zika virus were confirmed by RT-PCR only. There was some variation across countries in sample selection for testing, and the proportion of patients who tested positive for Zika ranged from 4.0%--38.1%. Approximately 50.0% of positive cases were from Trinidad and Tobago ([Table 1](#t1){ref-type="table"}).

###### Laboratory-confirmed Zika cases in 19 Caribbean Public Health Agency (CARPHA) member states, 1 October 2015--29 December 2016

  Country                                       Total cases for which samples were tested   Zika-positive cases   Test positivity (%)
  --------------------------------------------- ------------------------------------------- --------------------- ---------------------
  Anguilla                                      60                                          20                    33.3
  Antigua & Barbuda                             123                                         24                    19.5
  Bahamas                                       99                                          9                     9.1
  Barbados                                      130                                         40                    30.8
  Belize                                        392                                         61                    15.6
  British Virgin Islands                        180                                         17                    9.4
  Cayman Islands                                213                                         28                    13.2
  Dominica                                      381                                         78                    20.5
  Grenada                                       179                                         43                    24.0
  Guyana                                        198                                         42                    21.2
  Jamaica[a](#TFN1){ref-type="table-fn"}        223                                         9                     4.0
  Montserrat                                    31                                          5                     16.1
  Saint Lucia                                   192                                         52                    27.1
  Sint Maarten[b](#TFN2){ref-type="table-fn"}   383                                         146                   38.1
  St. Kitts & Nevis                             210                                         39                    18.6
  St. Vincent & the Grenadines                  302                                         83                    27.5
  Suriname[a](#TFN1){ref-type="table-fn"}       33                                          6                     18.0
  Trinidad & Tobago                             2 150                                       721                   33.5
  Turks & Caicos Islands                        154                                         24                    15.6
  Total                                         5 614                                       1 447                 25.8

Source:

CARPHA laboratory and surveillance data 2015--2016.

Only some specimens were referred to the CARPHA laboratory for testing. Testing was also performed in-country, but these results were not available to the CARPHA surveillance unit for inclusion at the time of these analyses.

Data submitted to CARPHA surveillance unit.

Case characteristics
--------------------

Of the 1 447 confirmed cases, 1 200 (83.0%) were female, of which 614 (51.0%) were pregnant. The age of cases ranged from 5 days to 90 years (median, 30 years); 59% were 20--39 years old ([Table 2](#t2){ref-type="table"}).

###### Characteristics of laboratory-confirmed Zika cases in 19 Caribbean Public Health Agency (CARPHA) member states, 1 October 2015--29 December 2016

  Characteristics                                          Confirmed cases (*n* = 1 447)                                      
  -------------------------------------------------------- ----------------------------------------- -------------- --------- ------------
  Sex (%)                                                                                                                     
                                                           Male                                      237 (16.0)               
                                                           Female                                    1 200 (83.0)             
                                                                                                     Pregnant (%)             
                                                                                                                    Yes       614 (51.0)
                                                                                                                    Unknown   10 (1.0)
  Median age, years (IQR[a](#TFN3){ref-type="table-fn"})                                                                      
                                                           All patients                              30 ([@B15])              
                                                           Pregnant women                            28 ([@B9])               
                                                           Children[b](#TFN4){ref-type="table-fn"}   7.5 ([@B8])              
  Age group, years (%)                                                                                                        
                                                           0--4                                      55 (4.0)                 
                                                           5--9                                      48 (3.0)                 
                                                           10--14                                    44 (3.0)                 
                                                           15--19                                    66 (5.0)                 
                                                           20--24                                    188 (13.0)               
                                                           25--29                                    264 (18.0)               
                                                           30--34                                    248 (17.0)               
                                                           35--39                                    156 (11.0)               
                                                           40--44                                    93 (6.0)                 
                                                           45--49                                    54 (4.0)                 
                                                           50--54                                    59 (4.0)                 
                                                           55--59                                    33 (2.0)                 
                                                           60--64                                    24 (2.0)                 
                                                           ≥ 65                                      115 (8.0)                

Source:

CARPHA laboratory and surveillance data 2015--2016.

IQR: interquartile range.

16 years or younger.

Clinical characteristics
------------------------

The symptoms most commonly reported by all cases were rash (87.0%), fever (63.0%), and arthralgia (60.0%). Conjunctivitis was reported by 33.0% of cases. Other symptoms included headache, chills, and myalgia.

There was a statistically significant difference in the proportion of males who reported rash, fever, conjunctivitis, headache, chills, and myalgia when compared to females. There was also a statistically significant difference in the proportion of adults who reported fever, arthralgia, and myalgia when compared to children ([Table 3](#t3){ref-type="table"}).

###### Clinical manifestation of Zika in laboratory-confirmed cases in 19 Caribbean Public Health Agency (CARPHA) member states, 1 October 2015--29 December 2016

  Clinical manifestation   All cases (n = 1 447)   Adults (n = 1 289)   Children[a](#TFN5){ref-type="table-fn"} (n = 158)   Male (n = 237)   Female (n = 1 200)   Pregnant women (n = 614)                                                                             
  ------------------------ ----------------------- -------------------- --------------------------------------------------- ---------------- -------------------- ----------------------------------- ----- ------ ------- ------------------------------------- ----- ------
  Rash                     1 255                   87.0                 1 111                                               86.0             144                  91                                  191   81.0   1 055   89.0[b](#TFN6){ref-type="table-fn"}   560   91.0
  Fever                    913                     63.0                 791                                                 61.0             122                  77[b](#TFN6){ref-type="table-fn"}   202   86.0   707     59.0[b](#TFN6){ref-type="table-fn"}   330   54.0
  Arthralgia               874                     60.0                 809                                                 63.0             65                   41[b](#TFN6){ref-type="table-fn"}   152   64.0   717     60.0                                  341   56.0
  Conjunctivitis           476                     33.0                 431                                                 33.0             45                   28                                  94    40.0   377     31.0[b](#TFN6){ref-type="table-fn"}   169   28.0
  Headache                 200                     14.0                 176                                                 14.0             24                   15                                  53    22.0   147     12.0[b](#TFN6){ref-type="table-fn"}   46    7.0
  Chills                   171                     12.0                 158                                                 12.0             13                   8                                   43    18.0   128     11.0[b](#TFN6){ref-type="table-fn"}   52    8.0
  Myalgia                  147                     10.0                 138                                                 11.0             9                    6[b](#TFN6){ref-type="table-fn"}    38    16.0   108     9.0[b](#TFN6){ref-type="table-fn"}    26    4.0

Source:

CARPHA laboratory and surveillance data 2015--2016.

16 years or younger.

*P* \< 0.05 for Fisher\'s exact test.

Hospitalizations and deaths
---------------------------

No Zika-related hospitalizations were reported; however, Suriname reported four deaths associated with the virus during the review period ([@B14]). It is unknown whether these cases had preexisting comorbidities prior to infection with the virus.

Reported disease outcomes
-------------------------

Four confirmed cases of congenital syndrome associated with Zika virus infection were reported from three countries during the period: two in Suriname and one each in Grenada and Trinidad and Tobago. A total of 121 cases of GBS were reported from 10 countries, with 13 reported cases laboratory-confirmed for Zika virus ([Table 4](#t4){ref-type="table"}).

###### Congenital syndrome and Guillain--Barré syndrome (GBS) associated with Zika virus infection in 19 Caribbean Public Health Agency (CARPHA) member states, 1 October 2015--29 December 2016

  Country                        Number of pregnant women tested for Zika virus   Confirmed congenital syndrome associated with Zika virus infection[a](#TFN7){ref-type="table-fn"}   Reported cases of GBS   Cases of GBS laboratory-confirmed for Zika
  ------------------------------ ------------------------------------------------ --------------------------------------------------------------------------------------------------- ----------------------- --------------------------------------------
  Anguilla                       1                                                0                                                                                                   0                       0
  Antigua & Barbuda              13                                               0                                                                                                   0                       0
  Bahamas                        2                                                0                                                                                                   0                       0
  Barbados                       32                                               0                                                                                                   4                       0
  Belize                         13                                               0                                                                                                   0                       0
  British Virgin Islands         2                                                0                                                                                                   0                       0
  Cayman Islands                 1                                                0                                                                                                   0                       0
  Dominica                       9                                                0                                                                                                   2                       0
  Grenada                        7                                                1                                                                                                   10                      3
  Guyana                         4                                                0                                                                                                   13                      0
  Jamaica                        0                                                0                                                                                                   30                      4
  Montserrat                     0                                                0                                                                                                   0                       0
  Saint Lucia                    37                                               0                                                                                                   6                       0
  Sint Maarten                   6                                                0                                                                                                   0                       0
  St. Kitts & Nevis              7                                                0                                                                                                   1                       0
  St. Vincent & the Grenadines   20                                               0                                                                                                   7                       0
  Suriname                       0                                                2                                                                                                   15                      4
  Trinidad & Tobago              459                                              1                                                                                                   33                      2
  Turks & Caicos Islands         1                                                0                                                                                                   0                       0
  Total                          614                                              4                                                                                                   121                     13

Source:

CARPHA laboratory and surveillance data 2015--2016.

([@B14]).

Public health response
----------------------

During the pre-epidemic period, CARPHA activated its Incident Management Team and issued a news release ([@B24]). CMS were encouraged to enhance surveillance and vector control activities and to provide local physicians with materials to assist them with recognizing the classic symptoms of Zika. Key partners such as the Caribbean Tourism Organization, the Caribbean Hotel and Tourism Association, PAHO, and the CDC were contacted to apprise them of the situation and to coordinate support to CMS.

Early in the epidemic, CMS developed guidelines for the clinical management of patients accessing health care. Insecticide-treated bed nets were distributed to hospitals and other health care settings for use by infected patients. As the epidemic progressed, patients were encouraged to use mosquito repellent and to self-quarantine to minimize spread to other family members and the community. Island-wide public awareness campaigns targeting both residents and visitors were carried out, with a focus on densely populated areas; activities included posting flyers and banners and disseminating public service announcements. Vector control measures were stepped up in all CMS in communities, schools, health facilities, and hotels. Surveillance for acute flaccid paralysis (AFP), a regional syndrome routinely used for the early detection of poliovirus, was used to detect cases of GBS associated with the Zika virus.

In the post-epidemic period, several workshops and meetings, including lessons on identifying the virus, were held in collaboration with partner agencies. Some CMS developed 1) support packages (counseling and social protection) for families caring for children with microcephaly and other congenital anomalies, and 2) structured assessment protocols for monitoring child growth and development.

DISCUSSION
==========

During the epidemic period, 1 October 2015--29 December 2016, 5 614 cases from 19 CMS were tested for arboviral pathogens. Approximately 40% of specimens received at CARPHA--Trinidad were from Trinidad and Tobago. This can be explained by the close proximity of Trinidad\'s Public Health Laboratory to CARPHA--Trinidad. Of the 5 614 cases, 1 447 tested positive for Zika virus. The majority of confirmed cases were female (83%), and approximately 50% of the women were pregnant. This was expected, as pregnant women were one of the high-risk groups preferentially sampled, due to the association of congenital syndrome with Zika virus infection. Although no CMS reported sexually transmitted Zika cases, transmission of the virus via sex is plausible. Zika cases occurred in all age groups, but the age group most frequently tested was 20--39 years, similar to the outbreaks in Yap Island, Micronesia, and Salvador, Brazil ([@B9], [@B25]). This age group included women of child-bearing age, suggesting both short- and long-term economic effects from the disease, and a possible increased burden on health and social systems, due to complications arising from Zika infection during pregnancy. Of the 614 pregnant women tested for Zika virus, four cases of confirmed congenital syndrome associated with Zika virus infection were reported during the period ([@B14]), similar to reports from Brazil and French Polynesia ([@B26], [@B27]). There was some difficulty in obtaining data on the expected and observed cases of congenital anomalies in CMS. While some CMS followed the cohort of pregnant women who reported Zika-like symptoms during pregnancy, and evaluated the fetus during pregnancy and after birth, the extent and duration of subsequent postnatal follow-up is unknown and requires further research.

Peak cases were observed in August after the start of the rainy season (usually July--December). This temporal trend was similarly observed in Yap Island, French Polynesia, and Rio de Janeiro, Brazil (9, 14, 28). During the 2013--2014 chikungunya epidemic in some CMS, chikungunya cases demonstrated a similar trend, with peak cases during August--September 2014.[^a^](#fn3){ref-type="fn"} Recent work conducted by Mordecai et al. suggests that Zika virus transmission by *Ae. aegypti* and *Ae. albopictus* can occur between 18°C and 34°C, with transmission peak at 26°C--29°C ([@B29]). The tropical-to-subtropical conditions experienced in the Caribbean suggest temperature and climate may contribute to arboviral transmission. Increased rainfall contributes to increased breeding sites and thus increased mosquito populations.

Surveillance for Zika was implemented relatively quickly in CMS, following previous experience from the 2013--2014 chikungunya epidemic. Suriname was the first CMS to report autochthonous Zika transmission, in October 2015; after this, surveillance was enhanced in all CMS. No significant rise in reported cases of UDF was noted in Suriname\'s national surveillance data during September 2015. Retrospective investigation showed that Suriname\'s first four autochthonous Zika cases experienced onset of symptoms the week beginning 4 October 2015 (EW 40). These four cases did not have a history of recent travel from Suriname, were not related to each other, and did not reside in the same place. After confirmation of the initial cases, a significant increase in UDF was observed in Suriname\'s national surveillance in both the under- and over-5--year age groups. A similar trend was observed in a few other countries and was likely due to enhanced surveillance activities, public health messages about the disease, and presentation of persons with more severe symptoms for health care services.

As testing to detect the virus in mosquitoes was not performed, it is difficult to determine with certainty the mosquito species that contributed to virus transmission. The ubiquitous nature of *Ae. aegypti* and documented evidence that this species is a vector of dengue, chikungunya, and other arboviruses in the Caribbean suggests *Ae. aegypti* could have been a vector of Zika virus during the epidemic ([@B30]-[@B32]).

Detection of Zika virus RNA in serum of acutely ill patients in the absence of other arboviruses provided evidence that the epidemic was caused by Zika virus. While dengue is endemic, and the chikungunya virus was introduced during the 2013--2014 chikungunya epidemic, none of the patients tested yielded concurrent positive tests for the presence of dengue or chikungunya virus. Low laboratory detection of dengue and chikungunya virus during the review period was likely due to the fact that the Zika epidemic began soon after the chikungunya epidemic, so although chikungunya transmission was likely low, a few cases were still occurring.

Genotypic sequencing determined that the strain circulating in the region was the Asian strain, which is closely related to the strain that circulated in French Polynesia in 2013 ([@B26]). Clinical signs and symptoms of Zika virus infection were consistent with those described by both the French Caribbean and Brazil, with rash being the most prominent symptom reported by patients ([@B5], [@B28]). There were no reported hospitalizations attributed to the virus during the review period; however, Suriname reported four deaths attributed to the virus ([@B14]). It is unknown whether these cases had preexisting comorbidities prior to infection with the virus.

Surveillance for GBS related to Zika infection differed across the CMS, with some countries using the AFP syndrome as a criterion for detection of GBS cases related to Zika infection. During the period, a total of 121 GBS cases were reported from 10 CMS, with 13 GBS cases laboratory-confirmed for Zika virus. There was some difficulty in obtaining data on the expected and observed cases of GBS in CMS. Data reported by Suriname showed a 400% increase in the incidence of GBS during the weeks of Zika virus transmission compared to pre-Zika baseline incidence ([@B33]). This evidence indirectly supports the association between Zika virus and GBS.

A number of strategies were implemented during the Zika epidemic, including public awareness campaigns and vector control measures (application of larvicides and fogging).

Limitations
-----------

This work has some limitations. First, cross-reactivity can occur in flavivirus serological assays. Therefore, prior to serological testing, samples from suspected Zika cases were screened for Zika virus using molecular testing (RT-PCR) ([@B23]). The authors believe that molecular testing for the virus in serum collected 1--5 days after onset of illness yielded acceptable results due to the high specificity and sensitivity of the RT-PCR technique used (100% and 95% respectively) ([@B23]). Second, while the overall Zika test positivity rate was estimated at 25.8%, individual CMS positivity rates during the epidemic ranged from \< 10% to 38%. Differences in positivity rates across CMS can be explained by several factors, including physician difficulty in identifying Zika cases, given the clinical manifestation of the disease common to other arboviral infections; selective sampling of cases for testing, with a bias toward high-risk patients as the epidemic progressed; and possible degradation of the virus in serum samples during storage and transport, if appropriate conditions were not maintained. Finally, attack rates were not calculated and compared across countries because some of the reported rates were suspected to be inaccurate. Potential reasons for unreliable rate estimates include differing sample selection methods utilized within individual CMS and, as 80% of cases are believed to be asymptomatic ([@B9]), the likelihood that mild or asymptomatic cases were missed.

Conclusions
-----------

The emergence and spread of Zika, a reemerging pathogen with the potential to become epidemic, was plausible due to the high volume of intra-regional and international travel, the ubiquitous nature of the *Ae. aegypti* vector, and a presumed Zika-naïve population. The epidemic highlights the need for continued vigilance and investment in surveillance systems and innovative prevention and control strategies.
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